Leserbrief
Interpreting Clonal Hematopoiesis Following [ 177 Lu]Lu-PSMA-617: Clinical Risk Versus Genomic Signal
Journal of Nuclear Medicine · 2026-06 · 67 (6) · 1007-1007
DOI: 10.2967/jnumed.126.272410 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 26.03.2026. Verfasst von Swayamjeet Satapathy und 2 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Satapathy, S., Aggarwal, P., & Sood, A. (2026). Interpreting Clonal Hematopoiesis Following [ 177 Lu]Lu-PSMA-617: Clinical Risk Versus Genomic Signal. Journal of Nuclear Medicine, 67(6), 1007-1007. https://doi.org/10.2967/jnumed.126.272410
Vancouver
Satapathy S, Aggarwal P, Sood A. Interpreting Clonal Hematopoiesis Following [ 177 Lu]Lu-PSMA-617: Clinical Risk Versus Genomic Signal. Journal of Nuclear Medicine. 2026;67(6):1007-1007. doi:10.2967/jnumed.126.272410
BibTeX
@article{Satapathy2026,
author = {Satapathy, Swayamjeet and Aggarwal, Piyush and Sood, Ashwani},
title = {Interpreting Clonal Hematopoiesis Following [ 177 Lu]Lu-PSMA-617: Clinical Risk Versus Genomic Signal},
journal = {Journal of Nuclear Medicine},
year = {2026},
volume = {67},
number = {6},
pages = {1007--1007},
doi = {10.2967/jnumed.126.272410}
}
EUVIMED